Background: Breast cancer is most common cancer and accounts for one-fourth of all
Background
Casein Kinase 2(CSNK2), a highly conserved, multifunctional serine/threonine protein kinase, is critically important for the regulation of different processes in eukaryotes, such as proliferation, differentiation, and apoptosis [1] [2] [3] . CSNK2 is ubiquitously expressed in all tissues but its level is elevated in tumor tissues including prostate [4] , mammary gland [5] , head and neck [6] , lungs [7] and kidney [8] . CSNK2 possess a heterotetrameric conformation with two catalytic and two regulatory subunits [9] .
CSNK2β supports the structure of the tetrameric complex, augments catalytic activity and stability of CSNK2 and can also function dependently with other catalytic subunits [10] [11] [12] [13] 9] .
In a mammalian cell, CSNK2β is phosphorylated at Ser 209 at its autophosphorylation site and at Ser 53B, in a cell cycle-dependent manner and in vitro by p34 cdc5 [14, 15] .
CSNK2β is responsible for recruitment of CSNK2 substrates or potential regulators such as Nopp140, p53, Fas-associated factor-1 (FAF-1), topoisomerase II, CD5 and fibroblast growth factor-2 (FGF-2) [16] [17] [18] [19] [20] [21] [22] . Yeast two-hybrid interaction showed that
CSNK2β interact with c-Mos and A-Raf protein kinases [23] [24] [25] . Ectopic expression of CSNK2β in mouse 3T3-L1 adipocytes and in CHO cells increased proliferation [26] . The proliferative effects of CSNK2β vary in different cell lines. Deletion of gene encoding CSNK2β in mice leads to a failure in development [27] .
To understand its physiological importance in the regulation of multiple candidate target proteins, we focused our study on the role of CSNK2β in the tumorigenesis of human breast cancer (MDA-MB-231 cell) in vitro. In the present study, we used the RNA interference strategy to knockdown the CSNK2β gene and study the gross oncogenic activity in an in-vitro cell-based system. We evaluated its clonogenic, invasive, proliferative and apoptotic properties in MDA-MB-231 cells using siRNA. We found that
CSNK2β regulates the cell proliferation by targeting NF-κB, Wnt, JNK and MAPK pathway proteins and also modulates the expression of PIN1 and PTOV1 oncogene.
Our findings suggest that CSNK2β can be used as a novel target for breast cancer therapy.
Materials and methods

Reagents
Lipofectamine RNAiMAX, TRIzol, Propidium Iodide, RNase were purchased from Invitrogen Corp (Carlsbad, CA, USA). siRNA was obtained from Qiagen (Hilden, 
Cell culture
MDA-MB-231 cell was purchased from National Centre for Cell Science (Pune, India).
The cells were cultured in L-15 medium supplemented with 10% FBS, penicillin (100 unit/ml) and streptomycin (100µg/ml). The cell culture was maintained at 37°C in humidified air containing 5% CO 2 .
Transfection
Cells were cultured in 6 well plates one day before siRNA transfection. We used 25 nanomolar of each siRNA and made complex in Opti-MEM media. Similarly, the complex of Lipofectamine RNAiMAX (4 µl/each well) and Opti-MEM was made and incubated for 5 minutes at room temperature. After that, both the complexes were mixed Antisense strand 5'-UGGUUGGCAAUGACACGCCGG-3'
Construction of CSNK2β Overexpression plasmid and transfection
CSNK2β was cloned into pcDNA 3.1(+) expression vector. minutes. The cell plating number was similar to siRNA transfection.
Cell viability assay
Cell viability was accessed with CTG assay (Promega, Madison, WI). Briefly, MDA-MB-231 cells were seeded in 96 well white culture plate at a density of 1000 cells per 180 µl of medium per well with 20 µl of siRNA complexes for CSNK2β and incubated at 37°C, 5% CO 2 and incubated for 24 hours. On the next day, the media containing the complex was changed with the fresh media and further incubated till 96 hours. The cells were treated in quadruplets with respective siRNA. The reagents were prepared according to manufacturer's protocol. After incubation 100 µl of fresh media was added to each well followed by 100 µl of reagent and kept on a shaker for 2 minutes to induce the cell lysis.
The plate was incubated for 10 minutes at room temperature to stabilize the luminescence signal. Luminescence was measured using microplate ELISA reader (Bio Tek, Winooski, Vermont, US). to PVDF membrane (100 volts for 1 hour). The membranes were blocked using 5% skim milk in Tris buffer saline with 0.1% tween20 (TBST) for 2 hours at room temperature. The blots were incubated with primary antibodies overnight at 4°c on a rocker followed by incubation with HRP conjugated secondary antibodies. The blots were developed using enhanced chemiluminescence (ECL, Biorad).
COLONY FORMATION ASSAY
MDA
β actin was developed as a loading control.
RNA extraction, cDNA preparation, and real time PCR
Cells were transfected for 72 hours with the respective siRNAs and RNA was extracted using TRIzol lysis reagent using manufacturers protocol. 2µg of RNA was taken and pretreated with DNase followed by cDNA synthesis with oligoDT primers. The thermocycler condition was 65° c, 5 min, 42°c, 60 min and 72°c (final extension). Real time PCR was done with iTaq SYBR green mix (Biorad) using ABI 700,(Invitrogen).
PCR was carried out at following conditions. 
Statistical Analysis
Data were represented as a mean ± standard deviation. The level of significance between two groups was calculated by t-test. P < 0.05 was considered statistically significant.
Results
Expression of CSNK2β is altered in a multitude of tumor types.
cBioPortal data shows that CSNK2β has alterations (mutation, amplification, and deep deletion) across the human cancer types. The histogram shows the potential cancer relevance of CSNK2β and high frequency of alteration in Breast (BCCRC xenograft) that prompted us to validate its function in breast cancer ( Figure 1 ) [28] . 
Silencing of CSNK2β inhibits the proliferation of MDA-MB-231 cells
Silencing of CSNK2β inhibits the colony formation of MDA-MB-231 cells
We also performed the clonogenic assay which associates with the tumor formation in vivo [29] . Cells were transfected with Scramble and CSNK2β siRNA in 6 well plates and At the same time, the percentage of cells in G0/G1 and S phase was reduced (Figure 4 A, B). These results suggest that knockdown of cells with CSNK2β inhibits the progression of cells via blocking the cell cycle at G2/M phase.
Silencing of CSNK2β induces chromatin condensation indicating apoptotic morphology
After 72 hours post-transfection with CSNK2β siRNA remarkable changes such as chromatin condensation and nuclear fragmentation was seen in the test samples compared to Scramble using Hoechst 33258 staining ( Figure 5A ). This morphological examination interprets that CSNK2β has a profound role in cell survival and silencing it drives the cells towards apoptosis.
Silencing of CSNK2β increases the intracellular ROS production thereby enhancing cell death
ROS possess double edge sword property both as oncogenic, maintaining sustained and increased proliferation of cancer cells as well as tumor suppressor leading to cell death when the aberrant increase in intracellular ROS arises due to any kind of stress [30] . The fine distinction between the ROS activity and the fate of the cells depend on the balance between pro-oxidant and antioxidant or redox status of the cells. It is a good idea to find oxidative stress modulators as an anti-cancer strategy [31] . In our experiment, we found the increased production of ROS in CSNK2β siRNA transfected cells compared to scramble siRNA transfected cells ( Figure 5B ). This data suggested the CSNK2β modulates the intracellular ROS production in MDA-MB-231 cells.
Silencing of CSNK2β induces the cell death of MDA-MB-231 cells by both apoptosis and autophagy mechanisms.
To unravel the cell death mechanism induced after the knockdown of CSNK2β, western blot analysis was performed to determine the level of proteins related to apoptosis after 72 hours of post-transfection. We found that there was increased expression of BAX (pro-apoptotic), decreased the level of Bcl-xL (antiapoptotic), activation of procaspase 3
with the increased expression of cleaved caspase 3. (Figure 6 A, B, C). Altogether these results showed that silencing of CSNK2β drives cell death via apoptosis.
Moreover, we also analyzed the expression of autophagy markers such as Beclin and LC3. They were both upregulated in CSNK2β siRNA transfected samples than Scramble siRNA. These findings showed that targeting CSNK2β in MDA-MB-231 triggers the cells towards both apoptosis and autophagy cell death pathway ( Figure 6 D, E).
CSNK2β regulates the expression of multiple oncogenic signaling pathways.
To uncover the gross activity of CSNK2β in MDA-MB-231 cells, we examined the expression of mRNA and proteins related to cell proliferation, survival, and cell cycle by real time PCR and western blotting. We performed the mRNA expression analysis of a number of genes in 72 hours post transfected samples and found that the mRNA level of p21, a cell cycle inhibitor was increased while the expression of survivin (metastatic marker), Nanog (transcription factor for stemness) and cyclin B1 was decreased following the knockdown of CSNK2β (Figure 7 A) . These results suggest the role of CSNK2β in the cell cycle, cancer stem cell proliferation, and metastasis.
To further elucidate the signaling pathways affected by the knockdown of CSNK2β, we studied the expression of proteins responsible for cell proliferation such as p-ERK, p38- (Fig 7 E) . Hence, our results
showed that MAPK pathway is regulated by CSNK2β. Targeting MAPK pathway is prerequisite for the treatment of triple-negative breast cancer (TNBC) [32] . Thus CSNK2β can be the target of choice against TNBC. Further knockdown of CSNK2β also inhibited the expression of β catenin (Wnt signaling pathway), PCNA (DNA replication and repair) and E2F1 (transcription factor) ( Figure 7F ). Silencing of CSNK2β abrogated the expression of NF-κB which is constitutively expressed in breast tumors ( Figure 7G ) [33] . We also studied the expression of integrin 1 beta, a heterodimeric receptor that senses both external and internal cues and has an important role in tumor biology.
CSNK2β siRNA inhibits the expression of Integrin 1β thus decreasing proliferation and invasion (Figure7 H).
Overexpression and Knockdown of CSNK2β affect the expression of PIN1 and
PTOV1.
From our previous study, we found that there was the functional relationship between PIN1, PTOV1, and CSNK2β. We have shown that all the three genes share the functional relationship through c-JUN expression that mediated the cancer progression in prostate cancer (PC3 cells). We proposed that these genes fall in the same pathway and mediates their function either by direct interaction with PIN1 or indirectly by promoting the oncogenesis of PIN1 [34] . So we were interested to find the relationship 
Discussion
Breast cancer is the most common cancer occurring in women of both developed as well as developing countries. It was estimated that 1.7 million new cases were diagnosed in 2012 which was 12% of all new cases and 25% of all cancers in women (https://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-cancer statistics). Mortality due to breast cancer has been decreasing due to early diagnosis, improved adjuvant therapy, low usage of hormone replacement therapy [35, 36] .
Despite all these advancements and outcomes, triple negative breast cancer still remains a major challenge. Statistics show that TNBC represents 10-15% of all breast cancer and has a poor prognosis compared to other subtypes of cancer (ER, PR, and HER2/Neu) [37] . Thus it is indispensable to explore the potential candidate target to reduce the rate of metastases, morbidity, and mortality due to breast cancer and especially TNBC. In our study, we chose to elucidate the role of CSNK2β in breast cancer (MDA-MB-231, a TNBC cell line) in in-vitro.
We Controlled production of ROS is beneficial for proliferation and viability of cancer cells but its elevated level may be genotoxic and cause apoptosis of cancer cells [30, 31] .
Microscopic study of CSNK2β silenced MDA-MB-231 cells showed the increase in ROS production and nuclear condensation. Both the features support that the cells were in the process of apoptosis after the silencing with CSNK2β siRNA. Studies on different isoforms of casein kinase and their subunits in eukaryotic biology and cancer have been studied [1] [2] [3] , but the possible mechanistic study of CSNK2β in cancer was unclear.
Although CSNK2β is a regulatory subunit of CSNK, it is highly conserved protein and possesses independent function. Thus we anticipate that finding the new molecules within the CSNK2β regulatory network will tease out its role in tumorigenesis. To get the further insight into the biological significance of this protein we performed the expression study of the key molecules related to cell proliferation, survival, cell cycle, apoptosis and autophagy-related genes by western blotting and real time PCR.
Although the improved chemotherapy and use of adjuvants have decreased death rates due to breast cancer, understanding the response to treatment and apoptosis is still a major concern [38] . Here we have shown the induction of BAX (proapoptotic), suppression of Bcl-xL( antiapoptotic), activation of procaspase 3 with an elevated level of cleaved caspase 3 in CSNK2β siRNA transfected sample suggesting the cell death via apoptosis. Paradoxically autophagy is utilized as a survival mechanism by tumor; it can also promote the caspase-independent form of cell death and can be used as a cancer treatment modality [39, 40] . Moreover, BECN1 and LC3 which are autophagy markers were increased in CSNK2β knockdown samples. Since it follows both apoptosis and autophagy cell death mechanism, CSNK2β is an interesting molecule for targeted cancer therapy.
Raf/MEK/ERK pathways are activated in many tumors (prostate, breast, leukemia, melanoma, thyroid) which transmit the signals from cell surface receptors to transcription factors and can be exploited for therapeutic intervention [41, 42] . In the present study, we found that CSNK2β regulates the expression of P-ERK, p38-α, c-MYC, MAPK8 proteins which are connected to MAPK pathway in MDA-MB-231 cells.
These data suggested that targeting CSNK2β might be a potential strategy to improve clinical outcomes in future. Numbers of studies have been carried out on the dysregulation of Wnt/β-catenin in human breast cancer and is good clinical and pathological marker with the poor survival outcome [43, 44] . Consistent with these reports, our data also showed that knockdown of CSNK2β down-regulates the expression β -.catenin. PCNA is earlier reported as a reliable marker to access the growth and predicting the prognosis in breast cancer [45] . Thus we investigated the effect of silencing of CSNK2β on PCNA and its downregulation supported the previous findings. A recent study on the interbreeding of MMTV-PyMT mice with E2F1, E2F2, or E2F3 knockout mice showed that in addition to cell cycle control E2F targets the number of genes related to angiogenesis, extracellular matrix modification, proliferation and survival of tumor cells which was important for metastasis [46] . We also found that CSNK2β reduces the expression of E2F1 which might affect a large fraction of genes in breast cancer. NF-κB expression leads to the induction of genes related to apoptosis, cell cycle, cell invasion which contributes to tumorigenesis, chemoresistance and radioresistance [47] . Our result showed that CSNK2β might regulate the cell proliferation through the NF-κB pathway. From wound healing experiment we deduce that CSNK2β has a remarkable role in cell migration. This was further supported by the decrease in integrin 1B, glycoprotein receptors that mediate anchorage and migration of cells via cell matrix and cell-cell interactions [48] . [49, 50] .
In continuation of our previous study [34] , we have shown that overexpression of CSNK2β increases the expression of PIN1 while silencing it decreases its expression.
Although the study on PIN1 and CSNK2α is reported previously our results provided a new avenue for further exploration. Also, we have shown that Overexpression of PIN1
and CSNK2β elevated the level of C-Jun and Knockdown by siRNA reduced the expression. There are several reports of PTOV1 and human breast cancer.
Overexpression of PTOV1 promotes tumor progression and is a predictor of poor prognosis in breast cancer [51] . Also, PTOV1 promotes the tumorigenicity by activating Wnt/β-catenin pathway in breast cancer [52] . In our study, we have shown an initial report that overexpression and knockdown of CSNK2β both increased and decreased the expression of PTOV1respectively.Our previous study on co-immunoprecipitation showed that PIN1 interacts with PTOV1. These results support our previous finding that PIN1, PTOV1 and CSNK2β fall in the same pathway and either directly interact or cooperatively promote the oncogenesis [34] .
This conjecture provides a new scope for further experiments and validations to establish the relationship between these molecules and decipher their role in cell proliferation, survival, migration, and cell death in breast cancer as well as other cancer models.
Conclusion
In summary, our findings from our laboratory have shown that silencing of CSNK2β with 
